Susan Hurst

2.3k citations

32 papers · 1.7k indexed · 1 hit paper · h-index 18

Pharmacology top 0.2%
Oncology top 5%
Molecular Biology
Computational Theory and Mathematics top 2%
Pediatrics, Perinatology and Child Health top 5%

Co-authors: Ruth Hyland J. Andrew Williams Dennis A. Smith Theunis C. Goosen S. Ball Barry Jones Vincent Peterkin Jeffrey R. Koup
Topics: Pharmacogenetics and Drug Metabolism (8 papers)Monoclonal and Polyclonal Antibodies Research (8 papers)Biosimilars and Bioanalytical Methods (7 papers)
Cited by: Pharmacology Oncology Computational Theory and Mathematics
Journals: Journal of Clinical Oncology Scientific Reports Neuroscience
Partner nations: United States United Kingdom

In The Last Decade

Susan Hurst

30 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

2004 687 citations J. Andrew Williams, Ruth Hyland et al. Drug Metabolism and Disposition profile →

Peers

Countries citing papers authored by Susan Hurst

Since Specialization

Citations

This map shows the geographic impact of Susan Hurst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Hurst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Hurst more than expected).

Fields of papers citing papers by Susan Hurst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Hurst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Hurst. The network helps show where Susan Hurst may publish in the future.

Co-authorship network of co-authors of Susan Hurst

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Hurst. A scholar is included among the top collaborators of Susan Hurst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Hurst. Susan Hurst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Marstacimab, an antitissue factor pathway inhibitor, combined with bypassing agents: effects on thrombin generation and in hemostatically normal rats 2025 ·Research and Practice in Thrombosis and Haemostasis ·Marjorie A. Peraza,(unknown),Susan Hurst,Madhu P. Sirivelu,Karrie A. Brenneman,Debra D. Pittman	1
2	Ocular Safety and Toxicokinetics of Bevacizumab-bvzr (Zirabev), a Bevacizumab Biosimilar, Administered to Cynomolgus Monkeys by Intravitreal Injection 2023 ·Journal of Ocular Pharmacology and Therapeutics ·Marjorie A. Peraza,Susan Hurst,Wenhu Huang,Bernard S. Buetow,Andrew J. Lickteig,(unknown),(unknown),Margaret E. Collins,Rani S. Sellers,(unknown)	0
3	Analysis of β-nerve growth factor and its precursor during human pregnancy by immunoaffinity-liquid chromatography tandem mass spectrometry 2023 ·Scientific Reports ·Jason Walsh,Joe Palandra,(unknown),Shibing Deng,Susan Hurst,Hendrik Neubert	4
4	Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model 2016 ·Annals of the Rheumatic Diseases ·Timothy P. LaBranche,Alison M. Bendele,(unknown),Kathryn E. Gropp,Susan Hurst,Cedo M. Bagi,(unknown),(unknown),David L. Shelton,Mark Zorbas	44
5	Key considerations in the preclinical development of biosimilars 2015 ·Drug Discovery Today ·Lynne A. Bui,Susan Hurst,Gregory L. Finch,(unknown),Ira Jacobs,Carol F. Kirchhoff,(unknown),Anne Ryan	46
6	Serum β-nerve growth factor concentrations in pregnant female, nonpregnant female, and male cynomolgus monkeys 2014 ·Neuroreport ·Hendrik Neubert,Tracey Clark,Shibing Deng,Susan Hurst	4
7	Developmental toxicity assessment of tanezumab, an anti-nerve growth factor monoclonal antibody, in cynomolgus monkeys (Macaca fascicularis) 2014 ·Reproductive Toxicology ·Christopher Bowman,Mark G. Evans,(unknown),Satoru Oneda,Mark T. Butt,Susan Hurst,(unknown),David L. Shelton,Cris Kamperschroer,Mark Zorbas	12
8	Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin®) 2014 ·BioDrugs ·Susan Hurst,Anne Ryan,(unknown),James M. McNally,(unknown),Gregory L. Finch,Michael W. Leach,Stephen Ploch,(unknown),Teresa A. Smolarek	39
9	Sciatic nerve regeneration is not inhibited by anti-NGF antibody treatment in the adult rat 2013 ·Neuroscience ·Karen L. Lankford,Edgardo J. Arroyo,Chang‐Ning Liu,(unknown),Mark Zorbas,David L. Shelton,Mark G. Evans,Susan Hurst,Jeffery D. Kocsis	8
10	How Current Understanding of Clearance Mechanisms and Pharmacodynamics of Therapeutic Proteins Can Be Applied for Evaluation of Their Drug-Drug Interaction Potential 2011 ·Drug Metabolism and Disposition ·Eugenia Kraynov,Steven W. Martin,Susan Hurst,Odette A. Fahmi,Martin E. Dowty,Carol Cronenberger,Cho‐Ming Loi,Bing Kuang,(unknown),Scott Fountain,Michel Awwad,Diane Wang	14
11	A multiple-dose toxicity study of tanezumab in cynomolgus monkeys 2010 ·Regulatory Toxicology and Pharmacology ·Mark Zorbas,Susan Hurst,David L. Shelton,Mark Evans,Deborah Finco,Mark T. Butt	24
12	Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction 2009 ·Drug Metabolism and Disposition ·Odette A. Fahmi,Susan Hurst,David R. Plowchalk,Jack Cook,Feng Guo,Kuresh Youdim,Maurice Dickins,Alex Phipps,Amanda Darekar,Ruth Hyland,R. Scott Obach	167
13	Synthesis and SAR of tolylamine 5-HT6 antagonists 2009 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Michael W. Wilson,Paul D. Johnson,Shelley R. Graham,(unknown),Robin L. Roof,Peter A. Boxer,Lisa Gold,Leonard T. Meltzer,(unknown),(unknown),Jeffrey E. Campbell,Ti‐Zhi Su,Susan Hurst,Chad Stoner,Jacob B. Schwarz	17
14	Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans 2007 ·Expert Opinion on Drug Metabolism & Toxicology ·Susan Hurst,Cho‐Ming Loi,Joanne Brodfuehrer,Ayman El‐Kattan	74
15	Atorvastatin Glucuronidation Is Minimally and Nonselectively Inhibited by the Fibrates Gemfibrozil, Fenofibrate, and Fenofibric Acid 2007 ·Drug Metabolism and Disposition ·Theunis C. Goosen,Jonathan Bauman,John A. Davis,Chongwoo Yu,Susan Hurst,J. Andrew Williams,Cho‐Ming Loi	45
16	A Case of Pulmonary Alveolar Proteinosis Treated With Whole Lung Lavage 2005 ·Dimensions of Critical Care Nursing ·(unknown),Susan Hurst	1
17	UDP-GLUCURONOSYLTRANSFERASE 2B7 IS THE MAJOR ENZYME RESPONSIBLE FOR GEMCABENE GLUCURONIDATION IN HUMAN LIVER MICROSOMES 2005 ·Drug Metabolism and Disposition ·Jonathan Bauman,Theunis C. Goosen,Meera Tugnait,Vincent Peterkin,Susan Hurst,(unknown),Mark A. Milad,Michael H. Court,J. Andrew Williams	16
18	DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOSbreakdown → 2004 ·Drug Metabolism and Disposition ·J. Andrew Williams,Ruth Hyland,Barry Jones,Dennis A. Smith,Susan Hurst,Theunis C. Goosen,Vincent Peterkin,Jeffrey R. Koup,S. Ball	687
19	Reaction Phenotyping in Drug Discovery: Moving Forward with Confidence? 2003 ·Current Drug Metabolism ·John A. Williams,Susan Hurst,Jonathan Bauman,Barry Jones,Ruth Hyland,John P. Gibbs,R. Scott Obach,S. Ball	39
20	A SIGNIFICANT DRUG-METABOLIZING ROLE FOR CYP3A5? 2003 ·Drug Metabolism and Disposition ·J. Andrew Williams,Jack Cook,Susan Hurst	34

About Susan Hurst

Susan Hurst is a scholar working on Pharmacology, Pharmaceutical Science and Oncology, having authored 32 papers that have together received 1.7k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (8 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Biosimilars and Bioanalytical Methods (7 papers). The work is most often cited by research in Pharmacology (937 citations), Oncology (587 citations) and Computational Theory and Mathematics (241 citations). Susan Hurst has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Ruth Hyland, J. Andrew Williams, Dennis A. Smith, Theunis C. Goosen, S. Ball, Barry Jones, Vincent Peterkin, Jeffrey R. Koup, Cho‐Ming Loi and Ayman El‐Kattan. Their work appears in journals such as Journal of Clinical Oncology, Scientific Reports and Neuroscience.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact